Lv3
270 积分 2022-02-23 加入
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
17小时前
待确认
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration
17小时前
已完结
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
1天前
已完结
Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
16天前
已完结
The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab
16天前
已完结
Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder
16天前
已完结
Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder
18天前
已完结
Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder
18天前
已完结
Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels
18天前
已完结
Comparative Pharmacology of Ofatumumab vs Ocrelizumab in Humanized CD20 Transgenic Mice (S9.007)
1个月前
已完结
皖公网安备34019202002308
